The last few days have felt a lot like March 2020 – that initial panic when we didn’t know how long the COVID pandemic era would last, or how far-reaching the damage would be.

And back then, we were able to publish a whole Coronavirus Shopping List report with no fewer than 13 buy opportunities. Some were oversold blue-chip value stocks, some were the “work-from-home” darlings lying in wait, and others were seeing immediate, unbelievable surges in demand.

All 13 names in that report went on to rally, some in a huge way, making it famous among our MegaTrends subscribers.

Now it’s like déjà vu on our screens. The Volatility Index (VIX) peaked at nearly 83 then – it’s reached as high as 50 in the past week.

Source: TradingView

Markets are swinging hard in both directions, hair-trigger reactions on any bit of news from the Trump administration signaling what comes next in this escalating global trade war.

At LikeFolio, we’ve gotten more phone calls in the last 48 hours than we have all year – from people trying to figure out what to do, or whether they should be doing anything at all.

TradeSmith Daily readers like Lucio who are searching for the positives in all this mess, asking: “With [the] market in terrible areas right now, where are the positive stocks to consider that LikeFolio is looking at?”

When everything is being sold off at once – even the strongest companies with solid demand trends – that’s when LikeFolio shines.

By tracking real-time consumer behavior – search trends, social mentions, web visits, app engagement – we’re able to surface opportunities early.

In March 2020, stock prices may have been moving the other direction… but we let consumers lead us to Chewy (CHWY), which ultimately paid off 160%… Redfin (RDFN): 189%…and Zoom (ZM): 192%.

All told, our subscribers walked away with an average gain of 100% from this one, particularly prescient Coronavirus Shopping List.

We’re seeing the early signs of something similar today.

Most investors are focused on the Magnificent 7 – Google (GOOGL), Amazon.com (AMZN), Apple (AAPL)… you know the ones.

These are great companies with strong consumer signals, and they’re likely trading at a discount. We think they’re worth watching.

But we’re also tracking smaller names with the potential to move higher… faster.

Let me give you a sneak peek at one of those “oversold,” under-the-radar names today.

This stock has all the tells of a classic divergence – its stock is down 62% (since February alone), yet LikeFolio data shows digital demand is up 62%.

When Wall Street expects one thing but activity on Main Street is telling us another, the profits can be explosive.

The Top Performer in the LikeFolio Universe Right Now
We’re currently tracking consumer demand and sentiment data on 494 companies – and one is breaking away from the pack in a big way.

Check out the chart below, which compares year-over-year digital demand growth for a few of the names on our radar right now:

You’ll see Hims & Hers Health (HIMS) at the very top, logging a 62% surge in website visits – significantly outperforming most, if not all, the names we track in our database.

If you’re familiar with the company’s business model, you know why this uptick has our attention.

Hims & Hers offers personalized treatments for notoriously “stigmatized” ailments through its ForHims and ForHers digital health platforms.

It’s a true one-stop-shop for health and wellness – patients can book online consultations with a vast network of physicians for as little as $39 and get prescriptions for everything from acne to serious mental health disorders.

Now, you’re starting to see why web visits are an extremely predictive metric for Hims & Hers.

Remember, too, I said the stock is down more than 60% from its February highs. This is where HIMS’ story becomes about more than just tariff-induced volatility.

This Oversold Story Is About More Than Just Market Panic
What you need to know about Hims & Hers is that in early 2024, the company jumped into the booming weight-loss market, selling compounded versions of semaglutide through its telehealth platform.

Semaglutide is the active ingredient in Novo Nordisk’s (NVO) ultra-popular GLP-1 drug, Wegovy. These copycat formulations, legal under FDA shortage exemptions, allowed Hims to offer patients a low-cost alternative during a period of limited Wegovy supply.

With a $165-per-month price tag, Hims undercut the $1,350 list price of branded Wegovy and rapidly captured demand, racking up $225 million in related revenue last year.

HIMS shares, meanwhile, went on a meteoric rise – from $7.39 a share in November 2023, when we issued our first buy alert on the stock, to an all-time high of $72.98 in February of this year… a nearly 900% rally.

But its strategy depended on one key regulatory condition: Wegovy’s official designation as a drug in shortage.

In early 2025, that changed.

The FDA removed semaglutide from its drug shortage list in February, meaning companies like Hims & Hers will no longer be permitted to sell compounded versions after April 22, 2025 (for pharmacies) or May 22, 2025 (for outsourcing facilities), unless there is a documented clinical necessity.

The stock dropped sharply as investors reassessed the company’s near-term prospects in the GLP-1 category…

Source: TradingView

The Market Is Missing the Bigger Picture
HIMS’ weight-loss strategy was never built solely on semaglutide – and the company’s growth story goes well beyond weight loss.

Hims & Hers has already seen success with oral weight-loss alternatives, which reached a $100 million revenue run rate in under seven months. These pills appeal to a wider pool of consumers, avoid complex logistics, and offer a more scalable, durable path forward.

It also has another FDA-approved GLP-1 up its sleeve with liraglutide, which became available on its platform in April.

The company’s ForHers offerings, in particular, are gaining significant traction. In February, LikeFolio picked up a more than 250% acceleration in web traffic to ForHers.com:

Hims & Hers has successfully applied its personalization playbook to categories like dermatology and mental health, scaling women’s dermatology subscribers by more than 100% year over year.

The company is building behind-the-scenes infrastructure to support its next phase of growth. It recently acquired a whole-body lab testing platform to improve how it evaluates patients for a range of treatments – from weight loss to hormonal health. It’s also investing in domestic peptide manufacturing, which allows HIMS to produce key ingredients used in popular therapies like GLP-1s.

This gives Hims & Hers more control over supply, lowers long-term costs, and sets it up to expand into other categories like metabolic optimization and preventive care.

With more than 2.2 million subscribers, improving margins, and rising revenue per user, the market is sleeping on HIMS’ potential.

This massively oversold stock is one of – if not THE – top performer in the LikeFolio Universe right now, when it comes to forward-looking consumer demand.

This could be one of the most lucrative setups we’ve seen all year.

Until next time,

Andy Swan

Source: Trade Smith